TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...

Tempus AI Inc (NASDAQ: TEM) came ... Spruce Point cited several reasons, including account irregularities and eroding ties with key clients like AstraZeneca, for its bet against the Nasdaq listed ...

Tempus AI TEM expects full-year 2025 revenues of $1.25 billion (up from the previous $1.24 billion guidance), which represents approximately 80% annual growth. The company also expects adjusted EBITDA ...

Tempus AI said it will work with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology that can gather biological and clinical insights, discover novel drug targets and ...

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear ...

The agreement with AstraZeneca expands on the strategic partnership between the two companies announced in 2021 and aims to leverage Tempus’ AI-enabled platform and vast repository of multimodal ...

The AstraZeneca deal is also significant for the long-term outlook. Tempus already reported interest from other pharmaceutical giants and may announce additional deals soon. Analysts Can Provide a ...

Tempus AI’s stock took a hit in trading May 28, falling 19% to $53.20 during the day following a short seller’s report that claimed the Chicago-based health tech company’s share price faces ...

Tempus AI Stock Sees +21% Gain in 3 Days: Is It a Buy After AZN Deal? Tempus AI has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca and Pathos AI.